THURSDAY, June 20, 2024 -- For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with...

Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular...

Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or...

On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp, a bispecific CD20-directed CD3 T-cell engager,...

COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved...

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular...

WEDNESDAY, July 3, 2024 -- For patients with refractory gastroesophageal reflux disease (GERD), those receiving antireflux mucosectomy (ARMS) have a...

June 20, 2024 -- Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full...

Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in the KLHL6 gene in diffuse large B-cell...

THURSDAY, June 27, 2024 -- Inhaled insulin is associated with improved hemoglobin A1c (HbA1c) levels over 16 weeks among adults with type 1 diabetes...